TOP TEN perturbations for 38516_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38516_at
Selected probe(set): 205508_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38516_at (205508_at) across 6674 perturbations tested by GENEVESTIGATOR:

myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):4.176076
Number of Samples:9 / 3
Experimental myotonic dystrophy study 4 (biceps brachii; DM-like)
Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):4.046624
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (deltoid muscle; DM-like)
Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (skeletal muscle; DM1) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):3.983511
Number of Samples:5 / 3
Experimental myotonic dystrophy study 4 (skeletal muscle; DM1)
Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

Becker muscular dystrophy study 3 (biceps brachii) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):3.8212557
Number of Samples:3 / 3
Experimental Becker muscular dystrophy study 3 (biceps brachii)
Biceps brachii biopsies obtained from patients with Becker muscular dystrophy (BMD).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):3.7247038
Number of Samples:8 / 3
Experimental myotonic dystrophy study 4 (skeletal muscle; DM2)
Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (biceps brachii; DM1) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):3.6295319
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (biceps brachii; DM1)
Biceps brachii biopsies obtained from patients with myotonic dystrophy type 1 (DM1).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (deltoid muscle; DM2) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):3.6100368
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (deltoid muscle; DM2)
Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):3.562231
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (biceps brachii; DM2)
Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (deltoid muscle; DM1) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):3.4216423
Number of Samples:2 / 3
Experimental myotonic dystrophy study 4 (deltoid muscle; DM1)
Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

basal cell carcinoma study 3 / normal epidermal keratinocytes

Relative Expression (log2-ratio):3.2628193
Number of Samples:4 / 2
Experimental basal cell carcinoma study 3
Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC).
Control normal epidermal keratinocytes
Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37°C in humidified air containing 5% CO2.

Organism: Homo sapiens
Gene: 38516_at
Selected probe(set): 204934_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38516_at (204934_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)

Relative Expression (log2-ratio):4.136117
Number of Samples:3 / 2
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (ptasc)
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy.

prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):3.8676538
Number of Samples:3 / 5
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

collecting duct carcinoma study 1 / normal kidney tissue (adult)

Relative Expression (log2-ratio):-3.1964474
Number of Samples:2 / 3
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue (adult)
Normal adult kidney tissue samples.

nephroblastoma study 2 / normal kidney tissue (adult)

Relative Expression (log2-ratio):-2.780693
Number of Samples:4 / 3
Experimental nephroblastoma study 2
Tumor tissue samples from the kidney of patients with Wilms’ tumor.
Control normal kidney tissue (adult)
Normal adult kidney tissue samples.

prostate cancer study 1 (prim.) / benign prostate tissue

Relative Expression (log2-ratio):2.4820566
Number of Samples:7 / 6
Experimental prostate cancer study 1 (prim.)
Primary prostate cancer samples.
Control benign prostate tissue
Benign prostate samples.

prostate cancer study 8 (tissue) / adjacent prostate tissue

Relative Expression (log2-ratio):2.344263
Number of Samples:5 / 5
Experimental prostate cancer study 8 (tissue)
Tumor tissue samples from patients with primary prostate cancer collected after radical prostatectomy.
Control adjacent prostate tissue
Histologically normal prostate tissue samples from patients with primary prostate cancer collected after radical prostatectomy.

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):-2.299882
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

2-(chloromethyl)pyridine hydrochloride study 1 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-2.2956934
Number of Samples:3 / 19
Experimental 2-(chloromethyl)pyridine hydrochloride study 1 (48h)
HepG2 cells exposed to 300μM 2-(chloromethyl)pyridine hydrochloride in DMSO solvent for 48 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

stem cell differentiation study 41 (T3pi) / stem cell differentiation study 41 (hES-T3 EB)

Relative Expression (log2-ratio):-2.2932606
Number of Samples:2 / 2
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):2.2784557
Number of Samples:2 / 3
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).